Evidence map›Paper›PMID 26466568›Full record

ArticleNature2015

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Martin Peifer, Falk Hertwig, Frederik Roels, Daniel Dreidax, Moritz Gartlgruber, Roopika Menon, Andrea Krämer, Justin L Roncaioli, Frederik Sand, Johannes M Heuckmann and 45 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06502210 (Identification of New Gene Spliceosomes in Neuroblastoma and Their Translational Application in Clinical Accurate Diagnosis and Therapy), which is not on this map. Cited by 347 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 1 pooled it
37.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06502210 unknown statusnot on this mapstarted 2024, after this paper: background citation

Identification of New Gene Spliceosomes in Neuroblastoma and Their Translational Application in Clinical Accurate Diagnosis and Therapy

Typeobservational_patient_registrySponsorAffiliated Hospital of Nantong UniversityRan2024 to 2024Enrolled20ConditionsNeuroblastomaArmsPersonalized surgical therapy of neuroblastoma
3 · Its place in the literature

Who cites it

347 citing papers in PubMed, 1 synthesis or guideline pooled it, 600 citations in OpenAlex.

  1. HGG advances · 2023
    Pooled it
  2. Article
  3. How telomere attrition protects against cancer.Nature reviews. Genetics · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

287 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors at 18 institutions in 4 countries.

Martin PeiferDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Falk HertwigCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Frederik RoelsCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Daniel DreidaxDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Moritz GartlgruberDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Roopika MenonDepartment of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany.
Andrea KrämerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Justin L RoncaioliDepartment of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center, Pittsburgh, Pennsylvania 15213, USA.
Frederik SandCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Johannes M HeuckmannNEO New Oncology AG, 51105 Cologne, Germany.
Fakhera IkramCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Rene SchmidtInstitute of Biostatistics and Clinical Research, University of Münster, 48149 Münster, Germany.
Sandra AckermannCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Anne EngesserDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Yvonne KahlertDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Wenzel VogelDepartment of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany.
Janine AltmüllerCologne Center for Genomics, University of Cologne, 50931 Cologne, Germany.
Peter NürnbergCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Jean Thierry-MiegNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, USA.
Danielle Thierry-MiegNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894, USA.
Aruljothi MariappanCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Stefanie HeynckNEO New Oncology AG, 51105 Cologne, Germany.
Erika MariottiNEO New Oncology AG, 51105 Cologne, Germany.
Kai-Oliver HenrichDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Christian GloecknerNEO New Oncology AG, 51105 Cologne, Germany.
Graziella BoscoDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Ivo LeuschnerDepartment of Pathology, University of Kiel, 24118 Kiel, Germany.
Michal R SchweigerFunctional Epigenomics, University of Cologne, 50931 Cologne, Germany.
Larissa SavelyevaDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Simon C WatkinsDepartment of Cell Biology, Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
Chunxuan ShaoDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Emma BellDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Thomas HöferDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Viktor AchterComputing Center, University of Cologne, 50931 Cologne, Germany.
Ulrich LangComputing Center, University of Cologne, 50931 Cologne, Germany.
Jessica TheissenDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Ruth VollandDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Maral SaadatiDivision of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Angelika EggertDepartment of Pediatric Oncology and Hematology, Charité University Medical Center Berlin, 10117 Berlin, Germany.
Bram de WildeCenter for Medical Genetics, Ghent University, 9000 Ghent, Belgium.
Frank BertholdDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Zhiyu PengBGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong, 518083 China.
Chen ZhaoCenter for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology School of Pharmacy and School of Life Sciences, Fudan University, Shanghai 201203, China.
Leming ShiCenter for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology School of Pharmacy and School of Life Sciences, Fudan University, Shanghai 201203, China.
Monika OrtmannDepartment of Pathology, University of Cologne, 50937 Cologne, Germany.
Reinhard BüttnerDepartment of Pathology, University of Cologne, 50937 Cologne, Germany.
Sven PernerDepartment of Prostate Cancer Research, Institute of Pathology, Center for Integrated Oncology Cologne-Bonn, University Hospital of Bonn, 53127 Bonn, Germany.
Barbara HeroDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
Alexander SchrammDepartment of Pediatric Oncology and Hematology, University Children's Hospital, 45147 Essen, Germany.
Johannes H SchulteDepartment of Pediatric Oncology and Hematology, Charité University Medical Center Berlin, 10117 Berlin, Germany.
Carl HerrmannInstitute of Pharmacy and Molecular Biotechnology, University of Heidelberg, 69120 Heidelberg, Germany.
Roderick J O'SullivanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center, Pittsburgh, Pennsylvania 15213, USA.
Frank WestermannDivision Neuroblastoma Genomics (B087), German Cancer Research Center, 69120 Heidelberg, Germany.
Roman K ThomasDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
Matthias FischerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DEHeidelberg University · DEGerman Cancer Research Center · DENational Institutes of Health · USState Key Laboratory of Genetic EngineeringUPMC Hillman Cancer Center · USBGI Group (China) · CNCharité - Universitätsmedizin Berlin · DEChristian-Albrechts-Universität zu Kiel · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEEpigenomics (Germany) · DEEssen University Hospital · DEGerman Cancer Society · DEGhent University Hospital · BETH Köln - University of Applied Sciences · DEUniversity of Münster · DEUniversity of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Leonard J. Appleman · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

Neuroblastoma is a malignant paediatric tumour of the sympathetic nervous system. Roughly half of these tumours regress spontaneously or are cured by limited therapy. By contrast, high-risk neuroblastomas have an unfavourable clinical course despite intensive multimodal treatment, and their molecular basis has remained largely elusive. Here we have performed whole-genome sequencing of 56 neuroblastomas (high-risk, n = 39; low-risk, n = 17) and discovered recurrent genomic rearrangements affecting a chromosomal region at 5p15.33 proximal of the telomerase reverse transcriptase gene (TERT). These rearrangements occurred only in high-risk neuroblastomas (12/39, 31%) in a mutually exclusive fashion with MYCN amplifications and ATRX mutations, which are known genetic events in this tumour type. In an extended case series (n = 217), TERT rearrangements defined a subgroup of high-risk tumours with particularly poor outcome. Despite a large structural diversity of these rearrangements, they all induced massive transcriptional upregulation of TERT. In the remaining high-risk tumours, TERT expression was also elevated in MYCN-amplified tumours, whereas alternative lengthening of telomeres was present in neuroblastomas without TERT or MYCN alterations, suggesting that telomere lengthening represents a central mechanism defining this subtype. The 5p15.33 rearrangements juxtapose the TERT coding sequence to strong enhancer elements, resulting in massive chromatin remodelling and DNA methylation of the affected region. Supporting a functional role of TERT, neuroblastoma cell lines bearing rearrangements or amplified MYCN exhibited both upregulated TERT expression and enzymatic telomerase activity. In summary, our findings show that remodelling of the genomic context abrogates transcriptional silencing of TERT in high-risk neuroblastoma and places telomerase activation in the centre of transformation in a large fraction of these tumours.

Indexed as

Cell Line, TumorCell Transformation, NeoplasticChromatinChromosomes, Human, Pair 5DNA HelicasesDNA MethylationEnhancer Elements, GeneticEnzyme ActivationGene AmplificationGene Expression Regulation, NeoplasticGene SilencingGenome, HumanHumansInfantNeuroblastomaN-Myc Proto-Oncogene ProteinATRX protein, humanChromatinDNA HelicasesMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsRNA, MessengerTelomeraseTERT protein, humanX-linked Nuclear Protein

Identifiers

PMID26466568
PMCPMC4881306
OpenAlexW2156509269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.